UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

 

Date of report (Date of earliest event reported)                  May 6, 2016                    

 

Accelerate Diagnostics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of incorporation)

 

 

001-31822  84-1072256
(Commission File Number)  (IRS Employer Identification No.)

 

3950 South Country Club, Suite 470, Tucson, Arizona  85714
(Address of principal executive offices)  (Zip Code)

 

(520) 365-3100

(Registrant’s telephone number, including area code)

 

 

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 5.07.Submission of Matters to a Vote of Security Holders.

 

The 2016 Annual Meeting of Stockholders of Accelerate Diagnostics, Inc. (the “Company”) was held on May 6, 2016. At the meeting, Lawrence Mehren, Mark C. Miller, John Patience, Jack Schuler, Matthew W. Strobeck, Ph.D. and Frank J.M. ten Brink were elected as directors, each to hold office until the Company’s next Annual Meeting of Stockholders or until his successor is elected and qualified. An advisory vote on the compensation of named executive officers (“say-on-pay”) and the adoption of the Accelerate Diagnostics, Inc. 2016 Employee Stock Purchase Plan were approved and ratified at the meeting. The Audit Committee’s appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016 was also ratified at the meeting.

 

The voting results of the director elections and other proposals, which were described in more detail in the definitive proxy statement relating to the 2016 Annual Meeting of Stockholders that the Company filed with the Securities and Exchange Commission on April 1, 2016, are set forth below.

 

Proposal No. 1 – Election of Directors

 

Director Nominee Votes For Votes Withheld Broker Non-Votes
Lawrence Mehren 35,779,681 2,614,606 8,704,770
Mark C. Miller 38,372,242 22,045 8,704,770
John Patience 38,372,242 22,045 8,704,770
Jack Schuler 37,626,745 767,542 8,704,770
Matthew W. Strobeck, Ph.D. 38,372,236 22,051 8,704,770
Frank J.M. ten Brink 38,371,942 22,345 8,704,770

 

Proposal No. 2 – Advisory Vote on Compensation of Named Executive Officers (“Say-on-Pay”)

 

Description of Proposal Votes For Votes Against Abstentions Broker Non-Votes
To approve, on an advisory basis, the compensation of the Company’s named executive officers 38,139,158 182,552 72,577 8,704,770

 

Proposal No. 3 – Approval of the Accelerate Diagnostics, Inc. 2016 Employee Stock Purchase Plan

 

Description of Proposal Votes For Votes Against Abstentions Broker Non-Votes
To approve the adoption of  the Accelerate Diagnostics, Inc. 2016 Employee Stock Purchase Plan 38,144,506 175,488 74,293 8,704,770

 

Proposal No. 4 – Ratification of Auditors

 

Description of Proposal Votes For Votes Against Abstentions
To ratify the appointment of Ernst and Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016 47,062,288 19,819 16,950

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

Date: May 9, 2016

ACCELERATE DIAGNOSTICS, INC.

(Registrant)

 

/s/ Steve Reichling                                

Steve Reichling

Chief Financial Officer